Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2025-02-11 00:00:00 ET · period of report 2025-02-11 · accession 0001213900-25-012238 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-02-11 | 2025-02-11 | ORMP | Gabay Avraham | CFO | A - Grant | $0.00 | +76.0K | 434.0K | +21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-11 | A | A | 34,000 | $0.00 | 392,040 | D | — | — | (F1) Represents shares issued on settlement of performance stock units ("PSUs") previously granted on June 20, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. |
| 2 | Common | Common Stock | 2025-02-11 | A | A | 42,000 | $0.00 | 434,040 | D | — | — | (F2) Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria. |